Search - tctmd.com

Displaying 261 - 277 of 277

Sort: Relevancy | Date

News Daily News

Canada Approves Ticagrelor in ACS Patients

June 02, 2011

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

News Daily News

Meta-analysis Demonstrates Mixed Evidence on CABG in ACS Patients Taking Clopidogrel

Caitlin E. Cox

May 27, 2011

News Daily News

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

Leah Lawrence

May 26, 2011

News Conference News

RECLOSE 2-ACS: Poor Responders Show Poor Outcomes Despite Higher Clopidogrel Dose

Caitlin E. Cox

May 18, 2011

News Daily News

High-dose Statins Reduce CIN in ACS Patients Receiving PCI

Jason Kahn

May 05, 2011

News Daily News

PLATO Substudy: Excess Arrhythmias with Ticagrelor Have No Clinical Impact

May 02, 2011

News Daily News

LANCELOT: Antiplatelet Agent Shows Positive Signs in Patients With ACS, Stable CAD

Jason Kahn

April 21, 2011

News Daily News

GPIs in Elective PCI: Older Drugs Still Have a Role

February 27, 2011

News Daily News

Early GPI More Effective When Paired with Upstream Clopidogrel in NSTE ACS

Caitlin E. Cox

February 10, 2011

News Daily News

Letters to Lancet Take on PCI Substudy of CURRENT-OASIS 7

Caitlin E. Cox

January 25, 2011

News Daily News

Researchers Accurately Predict Who Will Discontinue Clopidogrel

Jason Kahn

January 09, 2011

News Daily News

PLATO CABG Cohort: Ticagrelor Cuts Total and CV Mortality in Half

L.A. McKeown

January 03, 2011

News Daily News

Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding

Kim Dalton

August 30, 2009

CME

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Advertisement

Canada Approves Ticagrelor in ACS Patients

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Meta-analysis Demonstrates Mixed Evidence on CABG in ACS Patients Taking Clopidogrel

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

RECLOSE 2-ACS: Poor Responders Show Poor Outcomes Despite Higher Clopidogrel Dose

High-dose Statins Reduce CIN in ACS Patients Receiving PCI

PLATO Substudy: Excess Arrhythmias with Ticagrelor Have No Clinical Impact

LANCELOT: Antiplatelet Agent Shows Positive Signs in Patients With ACS, Stable CAD

GPIs in Elective PCI: Older Drugs Still Have a Role

Early GPI More Effective When Paired with Upstream Clopidogrel in NSTE ACS

Letters to Lancet Take on PCI Substudy of CURRENT-OASIS 7

Researchers Accurately Predict Who Will Discontinue Clopidogrel

PLATO CABG Cohort: Ticagrelor Cuts Total and CV Mortality in Half

Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding

Everyday Antiplatelet Decisions: Making the Right Choices

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content